Anvisa bans unregistered weight-loss pens containing retatrutide and tirzepatide due to safety risks

g1.globo.com (Portuguese)

Anvisa banned two unregistered weight-loss pen brands, including retatrutide, due to safety concerns. The ban follows a severe illness in a patient who used an illegal pen containing retatrutide, a substance not approved for sale globally. Retatrutide is still in testing phases for diabetes and obesity, and its unregulated sale poses significant health risks.


With a significance score of 2.3, this news ranks in the top 20% of today's 31294 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: